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Abstract
Background: Myofibroblasts contribute to fibrosis through the overproduction of extracellular matrix (ECM) proteins,
primarily type I collagen (COL-1) and fibronectin (FN), a process which is mediated in systemic sclerosis (SSc) by the
activation of fibrogenic intracellular signaling transduction molecules, including extracellular signal-regulated kinases 1
and 2 (Erk1/2) and protein kinase B (Akt). Selexipag is a prostacyclin receptor agonist synthesized for the treatment of
pulmonary arterial hypertension. The study investigated the possibility for selexipag and its active metabolite
(ACT-333679) to downregulate the profibrotic activity in primary cultures of SSc fibroblasts/myofibroblasts and
the fibrogenic signaling molecules involved.
Methods: Fibroblasts from skin biopsies obtained with Ethics Committee (EC) approval from patients with SSc, after
giving signed informed consent, were cultured until the 3rd culture passage and then either maintained in normal
growth medium (untreated cells) or independently treated with different concentrations of selexipag (from 30 μM to
0.3 μM) or ACT-333679 (from 10 μM to 0.1 μM) for 48 h. Protein and gene expressions of α-smooth muscle actin (α-SMA),
fibroblast specific protein-1 (S100A4), COL-1, and FN were investigated by western blotting and quantitative real-time PCR.
Erk1/2 and Akt phosphorylation was investigated in untreated and ACT-333679-treated cells by western botting.
Results: Selexipag and ACT-333679 significantly reduced protein synthesis and gene expression of α-SMA,
S100A4, and COL-1 in cultured SSc fibroblasts/myofibroblasts compared to untreated cells, whereas FN was
significantly downregulated at the protein level. Interestingly, ACT-333679 significantly reduced the phosphorylation of
Erk1/2 and Akt in cultured SSc fibroblasts/myofibroblasts.
Conclusions: Selexipag and mainly its active metabolite ACT-333679 were found for the first time to potentially
interfere with the profibrotic activity of cultured SSc fibroblasts/myofibroblasts at least in vitro, possibly through the
downregulation of fibrogenic Erk1/2 and Akt signaling molecules.
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Background
Fibrosis is a common feature in diseases characterized by
chronic tissue inflammation and damage, including sys-
temic sclerosis (SSc) [1]. In SSc, fibrosis follows the micro-
vascular/endothelial damage with activation of fibroblasts
and their transition into profibrotic myofibroblasts [1–3].
After their phenotype transition, myofibroblasts acquire an
increased persistent capability to synthesize and accumulate
extracellular matrix (ECM) proteins, such as type I collagen
(COL-1), and fibronectin (FN), beginning an aberrant
“wound healing” process that contributes to fibrogenesis
and finally to the systemic SSc fibrosis [4–6].
Myofibroblast transition and ECM overproduction are
known to be induced by several profibrotic mediators, in-
cluding transforming growth factor-β (TGFβ), endothelin-
1 (ET-1), cytokines and chemokines (such as IL-6 and
CCL18), whose circulating levels are increased in patients
with SSc. These mediators have been shown to regulate
the progression of fibrosis through the activation of intra-
cellular signaling transduction pathways, such as those
involving the activation of mitogen-activated protein kin-
ase (MAPK), phosphatidylinositol 3-kinase (PI3K)/Akt
and Wnt/β-catenin signaling [7–10]. Based on this
knowledge, the blockage of fibroblast-to-myofibroblast
transition and the attenuation of the profibrotic myo-
fibroblast activity and related ECM overproduction
might represent important steps in reducing the fi-
brotic process at least in SSc [11, 12].
Prostacyclin is an endothelium-derived eicosanoid that
contributes to the maintenance of cardiovascular homeo-
stasis, promotes both the proliferation and the differenti-
ation of vascular smooth muscle cells, and acts as an
inflammatory modulator [13]. The prostacyclin effects are
mainly mediated by the activation of the prostacyclin I2
receptor (IP receptor) and the subsequent accumulation
of intracellular cyclic adenosine monophosphate (cAMP)
[14]. The IP receptor is a member of the G protein
coupled receptor superfamily highly expressed in several
cell types, including vascular smooth muscle cells, leuko-
cytes, monocytes, and fibroblasts [14–18].
Selexipag is an IP receptor agonist characterized by a
non-prostanoid structure and it has been synthesized for
the treatment of pulmonary arterial hypertension (PAH)
[19]. Selexipag has one major active metabolite, ACT-
333679, which is also a selective IP receptor agonist, and
both compounds are characterized by specific binding
and high affinity to this receptor [20].
This study investigated the effects of selexipag and
ACT-333679 in reducing the activity of cultured skin
SSc fibroblasts and their ECM protein overproduction,
through the ability to interfere with the activation of
those intracellular signaling transduction molecules
involved in the regulation and progression of fibrosis,
primarily MAPK family members (i.e. extracellular
signal-regulated kinases 1 and 2 (Erk1/2)) and protein
kinase B (PKB or Akt).
Methods
Patients with SSc and HSs
Six female patients with SSc (mean age 63 ± 10 years), who
fulfilled the new European League Against Rheumatism
(EULAR)/American College of Rheumatology (ACR) cri-
teria for SSc, and five sex-matched healthy volunteer sub-
jects (HSs) (mean age 57 ± 8 years) were recruited from the
Divisions of Rheumatology and Dermatology at the
University of Genova in accordance with the Declar-
ation of Helsinki, after providing signed informed con-
sent and following the local Ethical Board Committee
approval (protocol ID: 237REG2015) [21]. Patients with
SSc had an “active” nailfold videocapillaroscopic (NVC)
pattern and their demographic and clinical characteris-
tics are summarized in Table 1.
Cell cultures and treatments
Skin fibroblasts were isolated from fullthickness biopsies
of the clinically involved skin of one third of the distal
forearm of patients with SSc and of HSs, in accordance
with the EULAR scleroderma trials and research
(EUSTAR) protocol and our recent studies [5, 22, 23].
For the in vitro experiments, human SSc and HS skin
fibroblasts were grown in Roswell Park Memorial Insti-
tute (RPMI) 1640 medium supplemented with 10% fetal
bovine serum (FBS), 1% penicillin-streptomycin, and L-
glutamine (Lonza Clonetic, Switzerland) and used at the
3rd culture passage.
The fibroblasts isolated from the biopsy sample from
each patient with SSc were independently cultured up to
80% of confluence and then maintained in serum-free
medium for 4 h. After starvation, a portion of these cells
was maintained in growth medium at 5% of FBS without
treatment (untreated cells) and another portion was
treated for 48 h with three different concentrations of
selexipag (30 μM, 3 μM, or 0.3 μM); a further portion
of cells was treated for 48 h with three different con-
centrations of ACT-333679 (10 μM, 1 μM or 0.1 μM)
(Actelion Pharmaceutics, Switzerland), in accordance
with recent studies [15, 24–26].
The fibroblasts isolated from the biopsy sample from
each HS were cultured up to 80% of confluence and
maintained in growth medium at 5% FBS for 48 h, after
starvation in serum-free medium for 4 h.
To assess the activation of intracellular signaling trans-
duction molecules involved in the regulation of fibrosis, hu-
man SSc skin fibroblasts were cultured up to 80% of
confluence and after starvation in serum-free medium for
4 h, the cells were maintained in growth medium at 5%
FBS without any treatment (untreated cells) or treated with
three different concentrations of ACT-333679 (10 μM,
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1 μM, or 0.1 μM, Actelion Pharmaceutics) for 15 min,
30 min, and 48 h.
Immunocytochemistry analysis
SSc and HS skin fibroblasts were cultured in Flexi PERM
chamber slides (5 × 103 cells/spot) (Millipore, Billerica,
MA, USA) and treated as described in “Cell cultures and
treatments”. At the end of treatment, the cells were fixed
in 2% paraformaldehyde and incubated with primary
antibodies (dilution 1:100) to human α-smooth muscle
actin (α-SMA) (Dako Cytomation, Denmark), COL-1
(Enzo Life Science, UK), and FN (Sigma-Aldrich, Milan,
Italy). Linked antibodies were detected by biotinylated
universal secondary antibody and then with the HRP-
streptavidine complex (Vector Laboratories, CA, USA).
The analysis of α-SMA expression and ECM protein syn-
thesis was performed in each experimental condition
evaluating the same number of cells by light microscopy
(magnification × 20) (Leica, Cambridge, UK).
Western blotting
For the evaluation of myofibroblast phenotype markers
and ECM proteins, cultured human SSc skin fibroblasts
were lysed with NucleoSpin RNA/protein (Macherey-
Nagel, Duren, Germany), whereas to assess the Erk1/2
and Akt activation, cultured cells were lysed in ice using
Radio-Immunoprecipitation Assay (RIPA) buffer (HEPES
20 mM, NaCl 0.15 M, Glycerol 10%, EDTA 1 mM, aproti-
nin 10 μg/ml, leupeptin 10 μg/ml, pepstatin 1 μg/ml,
PMSF 1 mM, Na3Vo4 1 mM, Sigma-Aldrich). The protein
quantification was performed by the Bradford method.
For every condition, 15 μg of protein was separated by
electrophoresis on 8% and 4–16% gradient trisglycine gels
(GenScript, New York, NY, USA) and transferred onto
Hybond-C-nitrocellulose membrane (Life Technologies
Ltd., Paisley, UK). After 1 h in a phosphate buffer solution
(PBS)1x containing tritonX 0.1% and nonfat powdered
milk 5% (Sigma-Aldrich), the membranes were incubated
overnight at 4 °C with primary antibodies anti-human
α-SMA (dilution 1:1000; Cell Signaling, MA, USA),
fibroblast specific protein-1 (FSP1 or S100A4, dilution
1:500; Santa Cruz Biotechnology, CA, USA), COL-1
(dilution 1:600; Enzo Life Science), and FN (dilution
1:1000; Sigma-Aldrich).
Primary antibodies anti-human phospho-Erk1/2 (di-
lution 1:2000), Erk1/2 (dilution 1:600), phospho-Akt
(dilution 1:300), and Akt (dilution 1:500) (Santa Cruz
Biotechnology) were used to investigate the activation
of intracellular signaling transduction pathways. The
membranes were subsequently incubated with second-
ary antibodies (dilution 1:2000; Cell Signaling) and
also incubated with primary HRP-conjugated antibody
to human glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) (dilution 1:5000; Cell Signaling) to confirm
similar loading of protein samples into the gels and
the efficiency in the electrophoretic transfer.
Protein synthesis was detected using the enhanced chemi-
luminescence system (Luminata Crescendo, Millipore) and
the densitometric analysis was performed by the UVITEC
Image Analysis System (UVITEC, Cambridge, UK). Western
blotting was performed in six independent experiments on
cultured human SSc skin fibroblasts.
Table 1 Demographic and clinical characteristics of patients with systemic sclerosis (SSc)
Sample ID
Parameters SSc1 SSc2 SSc3 SSc4 SSc5 SSc6
Age 51 58 56 78 65 72
Sex F F F F F F
RP duration (months) 108 168 36 720 180 288
Disease duration
(months)
108 168 24 48 36 288
Skin involvement lcSSc lcSSc lcSSc lcSSc lcSSc lcSSc
mRSS score 17 4 14 14 5 17
VCP pattern Active Active Active Active Active Active
ANA Positive Positive Positive Positive Positive Positive
Autoantibody Scl70 CENP Fibrillarin CENP CENP CENP
Organ involvement Yes (lung, esophagus) No No No No No
Therapy Ca2+ antagonists,
ACE inhibitors,
immunosuppressors,
ERAs, aspirin, vitamin D
Aspirin, aminaphtone,
angiotensin receptor
blockers
Aminaphtone,
vitamin D
Aspirin, steroids,
ACE inhibitors,
aminaphtone,
MTX
Aspirin Aminaphtone,
vitamin D
Demographic and clinical parameters of patients with SSc enrolled into the study
F female, RP Raynaud’s phenomenon, lcSSc “limited” cutaneous systemic sclerosis skin involvement, mRSS modified Rodnan skin score, VCP nailfold
videocapillaroscopy, ANA anti-nuclear antibody, Scl70 anti-topoisomerase antibody, CENP anti-centromere antibody, ACE angiotensin converting enzyme,
ERA endothelin receptor antagonist, MTX methotrexate
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Quantitative real-time polymerase chain reaction
(qRT-PCR)
Total RNA was obtained from cultured human SSc skin fi-
broblasts using NucleoSpin RNA/protein (Macherey-Nagel)
and quantified by nanodrop, which was also used to evalu-
ate the RNA integrity, in accordance with the manufac-
turer’s protocol (Thermo Scientific, Wilmington, USA). For
each experimental condition, firststrand complementary
DNA (cDNA) was synthesized from 1 μg of total RNA
using QuantiTect Reverse Transcription Kit (Qiagen,
Milan, Italy).
The qRT-PCR was performed on an Eppendorf Realplex
4 Mastercycler using Real MasterMix SYBR Green detec-
tion system (Eppendorf, Milan, Italy) in a total volume of
10 μL loaded in triplicate. Primers for α-SMA (NM_
001613), S100A4 (NM_002961), COL-1 (NM_000088), FN
(NM_002026), and βactin (NM_001101, housekeeping
gene) were supplied by Primerdesign (Primerdesign, UK).
The gene expression values were calculated using the
comparative ΔΔ cycle threshold (ΔΔCT) method and
corresponded to the expression level (fold increase) of
the target gene compared to untreated cells, taken as the
unit value [27]. In all qRT-PCR assays, the melting curve
was performed to confirm the specificity of the SYBR
green assay, and the qRT-PCR was performed on six
independent experiments on cultured human SSc skin
fibroblasts.
Statistical analysis
The statistical analysis was carried out by the non-
parametric Mann-Whitney test to compare unpaired
treatments. Any p value lower than 0.05 was consid-
ered as statistically significant. Results of western blot-
ting and qRT-PCR were analyzed as mean ± standard
deviation (SD).
Results
Selexipag and ACT-333679 reduced α-SMA and S100A4
protein synthesis and gene expression in cultured human
SSc skin fibroblasts
Cultured SSc skin fibroblasts maintained in growth
medium for 48 h without treatment (untreated cells) had
increased expression of α-SMA compared to cultured
HS fibroblasts, indicating their ongoing differentiation
and transition into activated myofibroblasts (Fig. 1a). In
cultured SSc fibroblasts, selexipag and ACT-333679 re-
duced the protein expression of α-SMA compared to
untreated cells at all tested concentrations, as observed
by immunocytochemistry analysis (Fig. 1b).
In these cells, the effects of selexipag and ACT-333679
on both the protein synthesis and the gene expression of α-
SMA and S100A4 (specific myofibroblast markers) were
evaluated by western blotting and qRT-PCR.
Selexipag significantly reduced the protein synthesis of
α-SMA at all tested concentrations compared to un-
treated cells (p < 0.05 for all) and that of S100A4 at
the concentration of 3 μM and 0.3 μM (p < 0.05 com-
pared to untreated cells) (Fig. 2).
Similarly to selexipag, all tested concentrations of
ACT-333679 significantly reduced the protein synthesis
of α-SMA and S100A4 compared to untreated cells
(α-SMA, p < 0.05 for all concentrations; S100A4, p < 0.05
for ACT-333679 10 μM and 1 μM, p < 0.01 for ACT-
333679 0.1 μM) (Fig. 2).
At the gene expression level, selexipag 30 μM,
3 μM, and 0.3 μM significantly downregulated α-SMA
(p < 0.05 for all), whereas only the concentrations of
3 μM and 0.3 μM induced significant downregulation
in the gene expression of S100A4 compared to
untreated cells (p < 0.05) (Fig. 3).
At the same time, ACT-333679 downregulated the gene
expression of these myofibroblast phenotype markers.
ACT-333679 1 μM and 0.1 μM significantly reduced the
gene expression of α-SMA compared to untreated cells
(p < 0.05, for both concentrations), whereas the down-
regulation induced by ACT-333679 10 μM was not sta-
tistically significant (Fig. 3). However, all three tested
concentrations of ACT-333679 significantly downregu-
lated the gene expression of S100A4 compared to un-
treated cells (p < 0.05 for ACT-333679 10 μM and
1 μM; p < 0.01 for ACT-333679 0.1 μM) (Fig. 3).
Selexipag and ACT-333679 decreased the ECM protein
synthesis and gene expression in cultured human SSc
skin fibroblasts
As observed on immunocytochemistry analysis, cultured
SSc skin fibroblasts maintained in growth medium for
48 h without treatment (untreated cells) had increased
production of both COL-1 and FN compared to HS skin
fibroblasts, confirming their ongoing activated profibro-
tic phenotype (Fig. 1a).
In cultured SSc fibroblasts, selexipag and ACT-333679
reduced the synthesis of both COL-1 and FN compared
to untreated cells (Fig. 2). Selexipag 3 μM and 0.3 μM
and ACT-333679 10 μM, 1 μM, and 0.1 μM induced
significant reduction of COL-1 synthesis (p < 0.05 vs. un-
treated cells), whereas FN production was significantly
decreased by all tested concentrations of selexipag and
ACT-333679 (p < 0.05 vs. untreated cells, for all concen-
trations of both compounds) (Fig. 2). All these data were
obtained by western blotting.
At the gene expression level, selexipag 3 μM and 0.
3 μM significantly downregulated COL-1 compared to
untreated cells (p < 0.05 for both) (Fig. 3). ACT-333679
10 μM, 1 μM, and 0.1 μM significantly downregulated
the gene expression of COL-1 compared to untreated
Cutolo et al. Arthritis Research & Therapy  (2018) 20:77 Page 4 of 11
cells (p < 0.05 for all) (Fig. 3). No significant modulatory
effects of selexipag and ACT-333679 were observed on
FN gene expression (Fig. 3).
ACT-333679 reduced both Erk1/2 and Akt
phosphorylation in cultured human SSc skin fibroblasts
Since ACT-333679 is the major active metabolite of
selexipag, its possible modulatory effect on Erk1/2 and
Akt activation was directly investigated in cultured SSc
skin fibroblasts.
Cultured untreated SSc fibroblasts showed the activation
of both Erk1/2 and Akt at 48 h, as observed through their
increased phosphorylation state (Fig. 4a). Interestingly,
ACT-333679 significantly reduced the phosphorylation
of both Erk1/2 and Akt compared to untreated cells
(p < 0.05 for all concentrations) (Fig. 4a). Moreover,
cultured SSc fibroblasts were treated for 15 min and
30 min in the presence or absence of ACT-333679, in
order to understand whether these mediators were
activated early.
It was interesting to note that cultured untreated SSc
fibroblasts showed a significant increase in Erk1/2 phos-
phorylation after 15 min and 30 min (p < 0.01 vs. time
zero (T0) for all time points), whereas ACT-333679
treatment was shown to significantly reduce Erk1/2
phosphorylation after 30 min of treatment (p < 0.05 vs.
untreated cells for all tested concentrations) (Fig. 4b).
At the same time, cultured untreated SSc fibroblasts had
a rapid and significant increase in Akt phosphorylation after
15 min and 30 min (p < 0.01 vs. T0 for both time points),
and ACT-333679 already contrasted this increased Akt
phosphorylation after 15 min, and significantly after 30 min
of treatment (p < 0.01 vs. untreated cells, for all tested con-
centrations) (Fig. 4b).
Discussion
The results of the study show for the first time that
selexipag and mainly its active metabolite ACT-333679
can potentially downregulate the profibrotic activity of
cultured SSc fibroblasts/myofibroblasts through the re-
duction of Erk1/2 and Akt phosphorylation/activation at
least in vitro.
The effect was characterized after treatment by the re-
duced synthesis of specific myofibroblast markers, such as
α-SMA and S100A4, and then of ECM proteins, COL-1
and FN.
Of note, cultured SSc skin fibroblasts, maintained for
48 h in growth medium, expressed high levels of α-SMA
compared to cultured HS skin fibroblasts, confirming
their ongoing transition into activated myofibroblasts.
Therefore, the ability of selexipag and ACT-333679
to downregulate the gene expression and the protein
synthesis of α-SMA and S100A4, seems to suggest a
possible role for this IP receptor agonist to interfere
with the fibroblast-to-myofibroblast transition.
It is recognized that in wound healing and in fibrotic
diseases, including SSc, the transition of fibroblasts into
profibrotic α-SMA+myofibroblasts is a fundamental event,
making these cells the key mediators of fibrogenesis
[28, 29]. The profibrotic capability of myofibroblasts is
Fig. 1 Evaluation of α-smooth muscle actin (α-SMA), type I collagen (COL-1), and fibronectin (FN) in cultured human skin fibroblasts isolated from
patients with systemic sclerosis (SSc) and healthy subjects (HSs). a Immunocytochemistry analysis of α-SMA, COL-1 and FN in cultured human SSc
and HS skin fibroblasts maintained in normal growth medium without treatment for 48 h. b Immunocytochemistry analysis of α-SMA in cultured
human SSc skin fibroblasts maintained in normal growth medium (untreated), treated with selexipag at the concentration of 30 μM, 3 μM, and
0.3 μM, and treated with ACT-333679 at the concentration of 10 μM, 1 μM, and 0.1 μM for 48 h
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linked to their overproduction and deposition of ECM
macromolecules, primarily COL-1 and FN, in the affected
tissues [30, 31]. The present in vitro study confirmed that
cultured SSc α-SMA+fibroblasts are characterized by
greater ECM protein synthesis compared to cultured HS
fibroblasts.
Therefore, the ability of selexipag and ACT-333679 to
significantly reduce the protein synthesis of COL-1 and
FN in cultured SSc skin fibroblasts/myofibroblasts might
suggest a possible antifibrotic action of the IP receptor
agonist.
Selexipag and ACT-333679 bind selectively and with
higher affinity to the IP receptor compared to other prosta-
cyclin analogs (such as beraprost or treprostinil), targeting
the pathway of prostacyclin activation and leading to vaso-
dilatory and anti-proliferative effects, as observed in several
mouse models of PAH [20, 30, 31]. In addition, ACT-
333679 is present at 3-fold to 4-fold higher levels and is
approximately 37-fold more potent in inducing in vitro ac-
tivation of human IP receptor than the parent compound,
suggesting that the metabolite is the major one responsible
for the selexipag effects in humans [32, 33]. In accordance
with these observations, the results of the present in vitro
study showed that in cultured SSc skin fibroblasts/myofi-
broblasts, ACT-333679 induced the same effects as selexi-
pag, but at a concentration three times lower than that of
the parent compound (selexipag 3 μM and 0.3 μM, ACT-
333679 1 μM and 0.1 μM). The concentrations of selexipag
and especially ACT-333679 were in accordance with several
in vitro studies [15, 24–26]. Moreover, the lowest ACT-
333679 concentration (0.1 μM) is in range with the values
of its bioavailability which were well-tolerated by the HSs
and were indicated by the area under the curve during a
dose interval of administration (AUCt), as reported in sev-
eral studies [25, 26].
It is interesting to note that selexipag and ACT-
333679 did not have a dose-dependent effect in redu-
cing the profibrotic activity of cultured SSc skin
fibroblasts/myofibroblasts. A possible explanation of
this might be related to the intrinsic variability in the
cellular response to treatments with selexipag and ACT-
333679 in cultured skin fibroblasts isolated from each
Fig. 2 Evaluation of the protein synthesis of myofibroblast phenotype markers and extracellular matrix macromolecules in cultured human systemic
sclerosis (SSc) skin fibroblasts. Western blotting and related densitometric analysis of the protein synthesis of α-smooth muscle actin (α-SMA), S100A4, type
I collagen (COL-1) and fibronectin (FN) in cultured human SSc skin fibroblasts maintained in normal growth medium (untreated), treated with selexipag at
the concentration of 30 μM, 3 μM, and 0.3 μM, and treated with ACT-333679 at the concentration of 10 μM, 1 μM, and 0.1 μM, for 48 h. For
each experimental condition, the value of the synthesis of α-SMA, S100A4, COL-1, and FN was normalized to that of the corresponding glyceraldehyde
3-phosphate dehydrogenase (GAPDH). The resulting value with each treatment was compared to that of the untreated cells (taken as a unit value), in order
to obtain the level of protein synthesis. A molecular weight (MW) lane was also included. The final results represent the mean ± standard deviation (SD) of
the values obtained from six independent experiments on cultured human SSc skin fibroblasts: *p< 0.05 and **p< 0.01 vs. untreated cells. kDa, kiloDalton
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enrolled patient with SSc. Therefore, the variability might
be reduced by increasing the number of patients with SSc
and the related experiments.
Another possible explanation for the absence of a dose-
response effect might depend on the expression level and
activity of the IP receptor on the cell surface of cultured
SSc skin fibroblasts/myofibroblasts. In a recent study it
has been observed that several cell types, including pul-
monary arterial smooth muscle cells (PASMCs), displayed
a moderate degree of constitutive IP receptor internaliza-
tion and treatment with prostacyclin analogs (such as
beraprost, treprostinil) induced strong depletion of this re-
ceptor from the cell surface, whereas the non-prostanoid
agonists selexipag and ACT-333679 did not induce these
effects [15]. Moreover, ACT-333679 1 μM and 10 μM
induced the same increase in the expression of the IP
receptor on the cell surface, which was higher than that
induced by ACT-333679 0.1 μM [15]. Based on this obser-
vation, it might be possible to hypothesize that the
concentrations of selexipag 0.3 μM and 3 μM and ACT-
333679 0.1 μM and 1 μM might be sufficient to bind to all
the IP receptors on the cell surface, inducing the activa-
tion of an intracellular signaling cascade that involves
increase in cAMP production. On the other hand, ACT-
333679 at the concentration of 0.1 μM, 1 μM, and 10 μM
induced overlapping effects in terms of cAMP production
and efficacy to contrast proliferation and fibrosis-related
readouts in human PASMCs in a saturable manner, deter-
mining an efficacy plateau [15].
Another important result of our in vitro study is that
selexipag and ACT-333679 exerted their effects effi-
ciently targeting the profibrotic activity of fibroblasts/
myofibroblasts of the skin, which represents one of the
tissues affected by the fibrotic process. These observa-
tions suggest that prostacyclin pathways may play an
important role in fibrotic diseases, including pulmonary
fibrosis, as already observed for the prostacyclin analog
iloprost, which reduces COL-1 synthesis through the in-
crease in cAMP production in SSc skin fibroblasts [34].
FN is a multifunctional macromolecule produced by fi-
broblasts that can modulate fibroblast-mediated collagen
gel contraction. According to this process, the activation
of the IP receptor was recently shown to inhibit FN re-
lease and fibroblast-mediated collagen gel contraction,
suggesting its possible contribution in tissue remodeling
through the action on fibroblasts [35]. The effects of selex-
ipag and ACT-333679, as observed at 48 h and limited to
the reduction in protein synthesis, might suggest that their
downregulatory effects on FN gene expression should be a
very early event, as already observed in the in vitro study
by Kamio et al. [35]. In this study the authors demon-
strated how the prostacyclin analog beraprost induced
Fig. 3 Evaluation of the gene expression of myofibroblast phenotype markers and extracellular matrix macromolecules in cultured human systemic
sclerosis (SSc) skin fibroblasts. Quantitative real-time polymerase chain reaction (qRT-PCR) and related analysis of the gene expression of α-smooth
muscle actin (α-SMA), S100A4, type I collagen (COL-1) and fibronectin (FN) in cultured human SSc skin fibroblasts maintained in normal
growth medium (untreated), treated with selexipag at the concentration of 30 μM, 3 μM, and 0.3 μM, and treated with ACT-333679 at the
concentration of 10 μM, 1 μM, and 0.1 μM, for 48 h. The final results represent the mean ± standard deviation (SD) of the values obtained
from six independent experiments on cultured human SSc skin fibroblasts: *p < 0.05 and **p < 0.01 vs. untreated cells
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downregulation of FN messenger RNA (mRNA) expres-
sion after 5 h of treatment, whereas the reduction in FN
release was observed after 48 h of treatment [35]. This re-
sult might be due to the activation of post-transcriptional
mechanisms induced by prostacyclin analogs and IP re-
ceptor agonists, which may be interesting to investigate.
Based on this observation, even shorter in vitro experi-
ments should be performed (at 4 h and 12 h).
Several molecules and growth factors contribute to the
induction of the profibrotic phenotype of fibroblasts, in-
cluding TGFβ1, ET-1 and cytokines (such as IL-6), through
the activation of fibrogenic intracellular signaling pathways
[7]. Among the molecules involved in these intracellu-
lar signaling pathways, Erk1/2 and Akt play an
important role in mediating the effects of TGFβ1 and
ET-1, which are considered key inducers of the
Fig. 4 Evaluation of the extracellular signal-regulated kinases 1 and 2 (Erk1/2) and protein kinase B (Akt) activation in cultured human systemic sclerosis
(SSc) skin fibroblasts. a Western blotting and related densitometric analysis of phospho-Erk1/2 (p-Erk1/2), Erk1/2, phospho-Akt (p-Akt) and Akt in cultured
human SSc skin fibroblasts maintained in normal growth medium (untreated) or treated with ACT-333679 at the concentration of 10 μM, 1 μM, and
0.1 μM for 48 h. The expression of phosphorylated proteins (p-Erk1/2 and p-Akt) was first normalized to that of the naïve proteins (Erk1/2 and Akt) and then
normalized to that of the related expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The resulting value of each treatment was compared
to that of the untreated cells (taken as the unit value): *p< 0.05 vs. untreated cells. b Western blotting and related densitometric analysis of phospho-Erk1/
2 (p-Erk1/2), Erk1/2, phospho-Akt (p-Akt) and Akt, in cultured human SSc skin fibroblasts maintained in normal growth medium (untreated) or treated with
ACT-333679 at the concentration of 10 μM, 1 μM, and 0.1 μM for 15 min and 30 min. The expression of phosphorylated proteins (p-Erk1/2 and p-Akt) was
normalized to that of the naïve proteins (Erk1/2 and Akt). The resulting value was then normalized to that of the related expression of GAPDH: #p< 0.01 vs.
time zero (T0); *p< 0.05 and **p < 0.01 vs. untreated cells. The final results represent the mean ± standard deviation (SD) of the values obtained from six
independent experiments on cultured human SSc skin fibroblasts
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fibrotic process and the levels of which are increased
in SSc [7, 36]. As recently demonstrated, cultured SSc
fibroblasts are characterized by increased phosphoryl-
ation of Erk1/2 and Akt when compared to HS fibro-
blasts suggesting the involvement of these molecules
in mediating the activated profibrotic phenotype of
SSc myofibroblasts [36].
The results of our in vitro study showed that cultured
SSc fibroblasts/myofibroblasts are characterized by early
phosphorylation and related activation of both Erk1/2
and Akt (15 min and 30 min) that was still present at a
later time point (48 h).
Erk1/2 are members of the MAPK family implicated
in several profibrotic signaling pathways [7, 37]. Previ-
ous investigations suggested that the activation of Erk1/
2, induced by TGFβ1, is responsible for the overexpres-
sion of α-SMA and COL-1 in cultured fibroblasts, pro-
moting the transition of these cells into profibrotic
myofibroblasts [38]. In addition, several studies have
reported that Erk1/2 can mediate the ET-1-induced
expression of collagen isoforms and contractile proteins
involved in the myofibroblast contraction and migra-
tion through the activation of the activator protein-1
(AP-1) transcription factor, contributing to the profi-
brotic effects of ET-1 [39–41].
Akt is a serine-threonine kinase that can engage multiple
downstream signaling substrates and pathways, including
the PI3K pathway, a Smad-independent intracellular signal-
ing pathway that mediates TGFβ-induced fibrosis [7]. Very
recent studies showed that the phosphorylation and the
related activation of Akt are primarily implicated in fibro-
blast/myofibroblast differentiation, migration and prolifera-
tion of pulmonary and cardiac fibroblasts stimulated with
TGFβ and ET-1 [42, 43].
Moreover, in previous investigations, the inhibition of
PI3K/Akt phosphorylation was found to interfere with
the expression of α-SMA in SSc lung fibroblasts and the
ability of these cells to contract the collagen gel matrix
mediated by ET-1 [44, 45].
Accordingly, the ability of ACT-333679 to significantly
reduce the phosphorylation of both Erk1/2 and Akt in
cultured SSc fibroblasts/myofibroblasts found in our
study, seems to further suggest that the effects of this IP
receptor agonist on these cells might involve downregu-
lation in the profibrotic signaling pathways.
One limitation of the study is that the antifibrotic
effects of selexipag and ACT-333679 were investigated
in in vitro cultures of human skin fibroblasts, so they
should also be replicated on lung fibroblasts, since this
IP receptor agonist was synthesized mainly for the treat-
ment of PAH.
If confirmed on lung fibroblasts, the vasodilator activ-
ity exerted by selexipag in SSc patients with PAH should
be integrated by important antifibrotic lung effects,
possibly exerting disease-modifying effects over the long
term. Moreover, to give an overview of selexipag and its
vasodilator effect, it is necessary to cite a recent random-
ized, placebo-controlled phase II study that showed how
selexipag did not reduce the number of Raynaud’s
phenomenon (RP) attacks compared to placebo in adults
with RP secondary to SSc, probably due to the differ-
ences between vascular effects in the systemic circula-
tion compared to the pulmonary vasculature [46]. It is
interesting to note that other therapies targeting the
prostacyclin pathways can have positive or negative
effects on RP based on the route of administration; in
accordance with this observation, different studies
highlighted that intravenous iloprost administration
showed efficacy in reducing the number, severity, and
duration of RP attacks whereas oral administration did
not have any of these effects [47, 48]. Therefore, the
route of administration of selexipag and other molecules
targeting prostacyclin pathway may have an impact on
the efficacy as indicated by the treatment response.
In addition, since Erk1/2 and Akt have been demon-
strated to contribute to the intracellular signaling path-
ways responsible for the profibrotic effects exerted by
TGFβ1 and ET-1, it might be interesting to investigate
whether selexipag and ACT-333679 may contrast this
action in cultured fibroblasts, both alone and in combin-
ation with selective TGFβ1 signaling blocking agents or
ET-1 receptor antagonists, such as macitentan.
Moreover, based on present results, a new study is cur-
rently in progress to investigate the functional relevance
of selexipag and its active metabolite, evaluating their
ability to reduce the enhanced contractile fibrotic
phenotype of SSc skin fibroblasts/myofibroblasts.
Conclusions
In conclusion, the in vitro study showed, for the first
time, the potential antifibrotic effects of selexipag and its
active metabolite in cultured SSc skin fibroblasts/myofi-
broblasts that might be determined through interference
in the activation of the Erk1/2 and Akt signaling path-
ways. The action was characterized by the reduction in
specific markers of activated myofibroblast phenotype
and the ECM protein production.
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